Last edition
News about "David Sinclair"
Life Biosciences Doses First Patient in Phase 1 ER-100 Optic Neuropathy Trial
Life Biosciences has dosed the first patient in its phase 1 trial of ER-100, an investigational epigenetic restoration therapy for glaucoma and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). The study marks a key milestone in evaluating a novel approach that targets the underlying causes of age-related vision loss.
David Sinclair | 09/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members